WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATC 5th levels

List of latest ATC/DDD decisions from the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the decisions should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline (see list). If no objections are received, the new ATC/DDD decisions will be considered final and included in the ATC/DDD Index. In the list final indicates that the date for objection has expired. The year of implementation in the ATC/DDD Index is given in the list.

Please note that the ATC and DDD alterations are only valid and implemented in the coming annual updates of January 1st.

ATC codeATC level nameDeadline for objection to temporary codesImplementation in ATC/DDD index
J06BD04ansuvimab01.02.20222023
C10BX19atorvastatin, amlodipine and candesartan01.02.20222023
J06BD07casirivimab and imdevimab01.02.20222023
S02AA18cefmenoxime 01.02.20222023
S01AA31cefmenoxime01.02.20222023
L01XX76ciltacabtagene autoleucel01.02.20222023
A16AB23cipaglucosidase alfa01.01.20222023
V09IX15copper (64Cu) dotatate01.02.20222023
J07BN03 1)covid-19, inactivated virus01.02.20222023
J07BN01 1)covid-19, RNA-based vaccine01.02.20222023
J07BN02 1)covid-19, viral vector, non-replicating01.02.20222023
H04AA02dasiglucagon 01.02.20222023
N06BA15dexmethylphenidate and serdexmethylphenidate01.02.20222023
S01AA29 dibekacin01.02.20222023
G04CA55doxazosin and finasteride01.02.20222023
L04AA58efgartigimod alfa01.02.20222023
A16AX21elivaldogene autotemcel01.02.20222023
A06AX09elobixibat01.02.20222023
S01LA09faricimab01.02.20222023
V09IX17fluorine (18F) PSMA-100701.02.20222023
S02AA17fosfomycin01.02.20222023
N04BA07foslevodopa and decarboxylase inhibitor01.02.20222023
V08CA12gadopiclenol01.02.20222023
J02AX07ibrexafungerp01.02.20222023
G04BD14imidafenacin01.02.20222023
D01AC22lanoconazole01.02.20222023
L01EB09lazertinib01.02.20222023
J07AX01leptospira vaccines01.02.20222023
H03AA51levothyroxine sodium and iodine compounds01.02.20222023
D01AE25liranaftate01.02.20222023
V10XX05lutetium (177Lu) vipivotide tetraxetan01.02.20222023
L01FD06margetuximab01.02.20222023
C01EB24mavacamten01.02.20222023
M05BX08menatetrenone01.02.20222023
S03CA07methylprednisolone and antiinfectives01.02.20222023
B06AX04mitapivat01.02.20222023
L01EB10mobocertinib01.02.20222023
L01FX21naxitamab01.02.20222023
D01AC21neticonazole01.02.20222023
J06BD08nirsevimab01.02.20222023
L01XY03nivolumab and relatlimab01.02.20222023
A01AB24octenidine01.02.20222023
N05AH53olanzapine and samidorphan01.02.20222023
A01AB25oxytetracycline01.02.20222023
L01CD51paclitaxel and encequidar01.02.20222023
L01EM05parsaclisib 01.02.20222023
A08AA51phentermine and topiramate01.02.20222023
A05BA10phospholipids01.02.20222023
V09IX16piflufolastat (18F)01.02.20222023
A01AC04prednisolone01.02.20222023
M03BX53pridinol, combinations01.02.20222023
J06BD06regdanvimab01.02.20222023
D11AH09ruxolitinib01.02.20222023
L01FX19sabatolimab01.02.20222023
J06BD05sotrovimab01.02.20222023
L01EX24surufatinib01.02.20222023
L01XX75tebentafusp01.02.20222023
A02BX15teprenone01.02.20222023
A16AX22tiomolibdic acid01.02.20222023
S01AE09tosufloxacin01.02.20222023
L01FX20tremelimumab01.02.20222023
L04AA57ublituximab01.02.20222023
N07XX18vutrisiran01.02.20222023
1) New ATC 5th level to be included in new ATC 4th level J07BN Covid-19 vaccines the Index 2023

Last updated: 2021-11-24